Last checked at 4 Jan 2019 10:02
hVIVO PLC
("hVIVO" or the "Company")
Award of Share Options
London, UK, 4 January 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that on 1st January 2019 it awarded the following options over ordinary shares of 5.0p each in the Company to Shelley Fraser:
Name | Position | Number of Share Options Awarded | Exercise price per Share | Date of Vesting | Percentage of issued ordinary share capital |
Shelley Fraser | Finance Director (PDMR) | 250,000 | 5.0p | 1 January 2022 | 0.1% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the persons discharging managerial responsibilities/persons closely associated | |||||||
a) | Name | Shelley Fraser | ||||||
2 | Reason for the notification | |||||||
a) | Position/ status | Finance Director (PDMR) | ||||||
b) | Initial notification/ Amendment | Initial Notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | hVIVO plc | ||||||
b) | Legal Entity Identifier | N/A | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument Identification code | Options over Ordinary Shares of 5 pence each
ISIN: GB00B6ZM0X53 | ||||||
b) | Nature of the transaction | Award of options over ordinary shares in the Company | ||||||
c) | Currency | GBP | ||||||
d) | Price(s) and volume(s) |
| ||||||
| ||||||||
e) | Aggregated information - Aggregated volume - Exercise price |
Options over 250,000 ordinary shares 5.0p | ||||||
f) | Date of the transaction | 1st January 2019 | ||||||
g) | Place of the transaction | London Stock Exchange, AIM | ||||||
For further information please contact:
hVIVO plc | +44 207 756 1300 |
Trevor Phillips (Executive Chairman) | |
Fleur Wood (Director, Investor Relations)
|
|
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | +44 203 727 1000 |
Simon Conway / Victoria Foster Mitchell |
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.